Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
subcutaneous
Pharma
FDA approves BMS' subcutaneous Opdivo with some limitations
The subcutaneous approval covers nearly all existing solid tumor indications for intravenous Opdivo with the exception of its combo uses with Yervoy.
Angus Liu
Jan 2, 2025 9:15am
ASH: Roche's subQ Lunsumio matches IV version in lymphoma
Dec 9, 2024 3:16pm
Merck moves a step closer with subcutaneous version of Keytruda
Nov 19, 2024 10:20am
Novartis tasks Lindy to turn biologics into at-home injectables
Aug 28, 2024 10:18am
Tracon seeks strategic options after injectable PD-L1 drug flop
Jul 2, 2024 4:32pm
ASCO surprise: J&J's injectable Rybrevant works better than IV
May 31, 2024 5:45pm